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Introduction
 
Type 2 diabetes mellitus is a progressive, chronic disease that
is increasing in prevalence worldwide, along with a rise in obesity,
one of its contributory factors [1]. It is characterized by insulin
resistance, causing a decrease in transport of glucose into fat
and muscle cells, and by a decrease in insulin secretion from the
pancreas [2]. The most frequently used initial pharmacological
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Abstract
 
Aims
 
To compare the effects of nateglinide plus metformin with gliclazide plus
metformin on glycaemic control in patients with Type 2 diabetes.
 
Methods
 
Double-blind, double-dummy, parallel group, randomized, multi-
centre study over 24 weeks. Patients with inadequate glucose control on maxi-
mal doses of metformin were randomized to additionally receive nateglinide
(
 
n
 
 = 133) or gliclazide (
 
n
 
 = 129). Changes from baseline in HbA
 
1c
 
, fasting plasma
glucose (FPG) and mealtime glucose and insulin excursions were examined.
 
Results
 
HbA
 
1c
 
 was significantly (
 
P <
 
 0.001) decreased from baseline in both
treatment groups (mean changes: nateglinide 
 
−
 
0.41%, gliclazide 
 
−
 
0.57%), but
with no significant difference between treatments. Proportions of patients
achieving a reduction of HbA
 
1c
 
 
 
≥
 
 0.5% or an end point HbA
 
1c
 
 < 7% were also
similar (nateglinide 58.1%, gliclazide 60.2%). Changes from baseline in FPG
were similarly significant in both treatment groups (nateglinide 
 
−
 
0.63, gliclazide
 
−
 
0.82 mmol/l). Reduction from baseline in maximum postprandial glucose
excursion were significant in the nateglinide group only (nateglinide 
 
−
 
0.71,
gliclazide 
 
−
 
0.10 mmol/l; 
 
P
 
 = 0.037 for difference). Postprandial insulin levels
were significantly higher with nateglinide compared with gliclazide. The overall
rate of hypoglycaemia events was similar in the nateglinide group compared
with the gliclazide group.
 
Conclusions
 
No significant difference was seen between nateglinide plus
metformin and gliclazide plus metformin in terms of HbA
 
1c
 
. However, the nate-
glinide combination demonstrated better postprandial glucose control.
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agent is metformin, but metformin monotherapy often fails to
maintain adequate glucose control over the long term. As a result
of advancing deterioration of 
 
β
 
-cell function, treatment with more
than one agent is usually required over time to achieve and maintain
good glycaemic control. Therefore, combining metformin with
other therapies such as sulphonylureas is the next step to maintain
successful control during the progressive course of the disease [3].
Sulphonylureas act by binding to sulphonylurea receptors
on pancreatic 
 
β
 
-cells, leading to increased secretion of insulin
[4]. Gliclazide is a second generation sulphonylurea that is
widely used in the treatment of patients with Type 2 diabetes
because it has similar efficacy to other sulphonylureas but a
lower risk of hypoglycaemia [5,6]. Nateglinide is a rapid-onset
insulinotropic agent unrelated to sulphonylureas [7,8]. Because
its effect on insulin secretion subsides when glucose levels
fall, nateglinide has less potential to elicit hypoglycaemia than
sulphonylureas [9]. Furthermore, nateglinide has minimal or
no effect on body weight, also probably because its insulino-
tropic effects are limited to the postprandial period and thus
nateglinide does not increase overall insulin exposure [10].
This study aimed to determine the efficacy and safety of the
combination of nateglinide plus metformin with the combina-
tion of gliclazide plus metformin, in patients for whom metformin
alone had failed to maintain adequate glycaemic control. Gliclazide
was selected as the most appropriate comparator because of its
lower risk of hypoglycaemia.
 
Patients and methods
 
This was a double-blind, double-dummy, parallel group, rand-
omized study carried out over a period of 24 weeks. Patients
were recruited from 24 centres across five countries, as listed in
the Acknowledgements. The study was carried out according to
Good Clinical Practice guidelines and the Declaration of Helsinki.
The protocol was approved by the appropriate ethical boards
and all patients provided written informed consent. Patients
were eligible if they had Type 2 diabetes for a minimum of
6 months and had received metformin monotherapy for at least
3 months; the patients also had to be on a minimum metformin
dose of 1000 mg per day continuously for at least 2 months
prior to study entry, but remain inadequately controlled by
medication, diet and physical exercise. Other inclusion crite-
ria were a baseline HbA
 
1c
 
 6.8–9.0%, and a body mass index
(BMI) between 20 and 35 kg/m
 
2
 
. In the 8 weeks preceding the
study, and throughout the study, patients remained on
their individual maximally tolerated dose of metformin.
Eligible patients received either nateglinide (Starlix, Novartis
Pharma, Basel, Switzerland) or gliclazide in combination with
metformin during the 24-week period. Randomization to
treatment was by a computer-generated schedule via an interac-
tive voice-responding system that assigned randomization on a
study-centre basis with a block size of 4. A double-dummy tech-
nique, using identical-looking nateglinide and placebo tablets
and identical-looking gliclazide and placebo capsules, was used
to blind study medication assignment. Treatment regimens of
nateglinide and gliclazide were started at the lowest levels
(60 mg three times a day before meals and 80 mg once per day,
respectively) and were titrated to the next dose level on a
monthly basis up to a maximum of 180 mg before meals and
240 mg per day, respectively, during the first 3 months. Dose
levels of study medication were increased if the fasting plasma
glucose (FPG) level was > 7 mmol/l, if the patient had not expe-
rienced any confirmed hypoglycaemic events (symptomatic
and/or asymptomatic events with plasma glucose concentration
 
≤
 
 4.0 mmol/l) and if the patient had not experienced more than
three hypoglycaemic events in the past month.
Efficacy was determined from the change in HbA
 
1c
 
 levels
from baseline to end point. Treatments were also assessed for
the percentage of patients reaching a treatment target (end
point HbA
 
1c
 
 < 7% and/or a decrease 
 
≥
 
 0.5% HbA
 
1c
 
), FPG and
body weight after 24 weeks of double-blind treatment. At base-
line and after 24 weeks, patients attended the clinic after an
overnight fast and received a standard breakfast consisting of
180 ml orange juice (grapefruit juice was not allowed), 60 g of
bread (white, wheat or rye), 20 g jam or preserves, 10 g butter
or margarine, 120 ml whole milk (3–4% fat) or the equivalent
amount of cheese plus 120 ml water, and decaffeinated coffee
or tea if desired. The meal was consumed within 15 min and
blood samples were taken at 0, 15, 30, 60, 90, 120, 180 and
240 min. Glucose and insulin concentrations were measured
and excursions were calculated from the difference between
fasting and postprandial levels; the area under the glucose curve
from 0 to 4 h (AUC
 
0
 
−
 
4 h
 
), adjusted for pre-meal values, was
calculated for patients who had at least six measurements. In
addition, insulin secretion index was calculated as: homeostatis
model assessment (HOMA)-B = [20 
 
×
 
 fasting insulin (mU/l)]/
[fasting glucose (mmol/l) – 3.5].
Determinations of HbA
 
1c
 
 and glucose and insulin from the
meal tests were carried out at two central laboratories, one in
Europe and one in the USA. Additionally, all patients were
provided with glucose-monitoring devices and supplies, and
were instructed on their use. Hypoglycaemic events were
analysed according to whether they were asymptomatic, symp-
tomatic or confirmed events; number of hypoglycaemic clinical
symptoms and incidence rate (number of symptoms per 100
patients per month) were also determined. Symptoms sugges-
tive of hypoglycaemia were tachycardia, palpitations, shakiness,
sweating and dizziness, hunger, blurred vision, impairment of
motor function, confusion or inappropriate behaviour. An event
was considered as confirmed if the self-monitored plasma glucose
value obtained at the time of the event was 
 
≤
 
 4.0 mmol/l (corre-
sponding to blood glucose value of 
 
≤
 
 3.6 mmol/l) or if hypogly-
caemia was classified as grade 2 (i.e. an episode with sufficient
neurological impairment that the patient was unable to initiate
self-treatment and required assistance or hospitalization). The
incidence rate of hypoglycaemic events per 100 patients per
month was calculated as [(total number of events across all
patients)/(total duration on treatment in days)] 
 
×
 
 30 
 
×
 
 100. All ad-
verse events were recorded; they were defined as serious if they
were fatal, life-threatening, required prolonged hospitalization,
resulted in persistent or significant disability/incapacity, consti-
tuted a congenital anomaly/birth defect or were considered
medically significant. For each adverse event, the relationship
to study drug treatment was classified by the investigator as sus-
pected or not suspected.
A planned sample size of 120 patients per treatment was
considered sufficient to detect an HbA
 
1c
 
 difference of 0.5% 
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with 90% power, assuming a dropout rate of 15% and an 
 
SD
 
 of
1.1. An 
 
ANCOVA
 
 model was used to test the null hypothesis that
nateglinide plus metformin combination therapy was as effective
as gliclazide plus metformin combination therapy. The primary
 
ANCOVA
 
 model included effects for treatment, study centre, baseline
HbA
 
1c
 
 and treatment by baseline HbA
 
1c
 
 interaction. Efficacy
analyses used the intent-to-treat population which included all
randomized patients with at least one post-baseline efficacy
evaluation, and safety was assessed for all randomized patients
with a post-baseline safety assessment. Evaluations from the
meal test were assessed for all patients with available data;
during storage and transport to the central laboratories a small
number of samples were lost and thus numbers of patients with
available data were reduced slightly, although analysis indi-
cated that the population with data was equivalent to the total
population. The statistical tests were conducted at the two-
sided significance level of 0.05.
 
Results
 
A total of 262 subjects were enrolled in the study and their
demographic details are summarized in Table 1, according to
treatment group; 133 were randomized to nateglinide plus
metformin and 129 to gliclazide plus metformin. The age, sex
and ethnicity profiles were similar across both treatment groups.
Most patients were Caucasian, with an overall mean age of
61.8 years and BMI of 29.0 kg/m
 
2
 
. Diabetic characteristics at
baseline were also comparable for the two treatment groups.
During the study, 33 patients discontinued treatment
prematurely; 13 (9.8%) patients from the nateglinide group
(two as a result of adverse events, one lost to follow-up, nine
who withdrew consent and one because of an unsatisfactory
therapeutic effect) and 20 (15.5%) patients from the gliclazide
group (eight due to adverse events, four lost to follow-up, six
who withdrew consent and two because of protocol violations).
The mean metformin doses at study entry were compar-
able (1921 and 1812 mg/day in the nateglinide and gliclazide
groups, respectively). The majority of patients in the nateglinide
group (59.4%) were titrated up to the highest dose level
(180 mg three times/day), compared with 35.7% of patients
in  the  gliclazide group attaining the highest dose level
(240 mg/day).
 
Glycaemic control
 
HbA
 
1c
 
 was significantly decreased in both treatment groups
when compared with baseline, but there was no difference in
efficacy between the two treatment groups (Table 2). The
proportion of patients with absolute reductions from baseline
in HbA
 
1c
 
 of 
 
≥
 
 0.5% were similar in both treatment groups.
End point HbA
 
1c
 
 was < 7.0% in slightly fewer patients in the
group treated with nateglinide than with gliclazide. However,
the proportion of patients achieving either an absolute reduc-
tion of HbA
 
1c
 
 
 
≥
 
  0.5% from baseline or an end point
HbA
 
1c
 
 < 7.0% was similar for both treatments.
Reductions from baseline in FPG were statistically significant
in both treatment groups, but the between-group difference in
change from baseline was not statistically significant (Table 2). A
small increase in mean body weight of less than 0.5 kg was
observed in both groups, but the changes from baseline were
not significant in either case and there was no significant
difference (
 
P =
 
 0.879) between treatments (data not shown).
Following the test meal, the changes from baseline to
24 weeks in maximum postprandial glucose were statistically
significant for both treatment groups, but the between-group
difference in change from baseline was not statistically signifi-
cant (Table 3). However, the decrease from baseline in maxi-
mum postprandial glucose excursion was significant in the
 
 
Nateglinide + 
metformin 
n = 133
Gliclazide + 
metformin 
n = 129
Age (years), mean ± SD 62.0 ± 11.0 61.6 ± 10.1
Range 28–84 38–80
Age group, n (%)
< 65 years 70 (52.6) 68 (52.7)
≥ 65 years 63 (47.4) 61 (47.3)
Sex, n (%)
Male 72 (54.1) 65 (50.4)
Female 61 (45.9) 64 (49.6)
Race, n (%)
Caucasian 131 (98.5) 124 (96.1)
Black 0 1 (0.8)
Asian/Chinese/Japanese 0 2 (1.6)
Other 2 (1.5) 2 (1.6)
BMI (kg/m2), mean ± SD 28.5 ± 3.5 29.5 ± 3.6
Duration of diabetes (years), mean ± SD 7.16 ± 6.30 6.70 ± 5.55
Baseline HbA1c (%), mean ± SD 7.67 ± 0.59 7.60 ± 0.58
Baseline FPG (mmol/l), mean ± SD 8.95 ± 1.49 8.73 ± 1.48
Table 1 Demographic and background 
characteristics by treatment group 
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nateglinide group only and the decrease was significantly
greater with nateglinide compared with gliclazide (
 
P =
 
 0.037).
The postprandial glucose AUC
 
0
 
−
 
4 h
 
, adjusted for pre-meal
values, was significantly decreased after 24 weeks of treatment
in the nateglinide group (
 
−
 
2.20 mmol*h/l; 
 
P
 
 < 0.001) but the
decrease in the gliclazide group (
 
−
 
0.61 mmol*h/l) was not
significant; the difference between the changes from baseline did
not reach significance (
 
P =
 
 0.054). The changes from baseline
in the 30-min and 2-h postprandial insulin level and 2-h insulin
excursion were larger in the nateglinide group compared with
the gliclazide group. The between-group differences in change
from baseline (in favour of nateglinide) were statistically
significant for each parameter (Table 3).
The insulin secretion index, as measured by HOMA-B
(Table  3), was slightly greater at baseline in the gliclazide
group than the nateglinide group, although the standard
 
Nateglinide + 
metformin 
n = 129
Gliclazide + 
metformin 
n = 118
Baseline HbA1c (%), mean ± SD 7.66 ± 0.59 7.57 ± 0.57
Change, least squares mean ± SE −0.41 ± 0.08 −0.57 ± 0.08
P-value for change < 0.001 < 0.001
Treatment difference, mean ± SD 0.17 ± 0.10
P-value for treatment difference 0.099
Response rates, n (%)
Reduction of HbA1c ≥ 0.5% from baseline 63 (48.8) 58 (49.2)
End point HbA1c < 7.0% 45 (34.9) 55 (46.6)
Reduction of HbA1c ≥ 0.5% from 
baseline or end point HbA1c < 7.0%
75 (58.1) 71 (60.2)
Baseline FPG (mmol/l), mean ± SD 8.49 ± 1.49 8.65 ± 1.49
Change, least squares mean ± SE −0.63 ± 0.17 −0.82 ± 0.18
P-value for change < 0.001 < 0.001
Treatment difference, mean ± SD 0.19 ± 0.21
P-value for treatment difference 0.375
Table 2 HbA1c changes from baseline to end 
point, proportion of patients with positive 
responses to predefined HbA1c criteria and 
fasting plasma glucose changes to end point
Table 3 Plasma glucose and insulin levels following a test meal, and insulin secretion index (HOMA-B), at study baseline and changes after 24 weeks 
of treatment of patients with Type 2 diabetes
 
 
Nateglinide + 
metformin
Gliclazide +
 metformin
Treatment 
difference
Maximum postprandial plasma glucose (mmol/l) n = 113 n = 107
Baseline, mean ± SD 15.19 ± 3.37 13.89 ± 3.08
Least squares mean change ± SE   −1.50 ± 0.28 −1.05 ± 0.30 −0.45 ± 0.37
P-value < 0.001 < 0.001 0.220
Maximum postprandial plasma glucose excursion (mmol/l) n = 109 n = 104
Baseline, mean ± SD 6.21 ± 3.12 5.39 ± 2.36
Least squares mean change ± SE  −0.71 ± 0.22 −0.10 ± 0.23 −0.61 (0.29)
P-value 0.001 0.663 0.037
30-min postprandial insulin (pmol/l) n = 111 n = 107
Baseline, mean ± SD 156.0 ± 118.6 156.8 ± 120.7
Least squares mean change ± SE  98.9 ± 12.1 32.5 ± 12.56  66.4 ± 15.7
P-value < 0.001 0.010 < 0.001
2-h postprandial insulin (pmol/l) n = 112 n = 100
Baseline, mean ± SD 218.2 ± 163.6 222.6 ± 182.9
Least squares mean change ± SE  83.9 ± 16.6 39.6 ± 17.8 44.3 ± 22.2
P-value < 0.001 0.028 0.047
2-h postprandial insulin excursion (pmol/l) n = 107 n = 97
Baseline, mean ± SD 152.2 ± 142.2 150.2 ± 166.4
Least squares mean change ± SE  75.5 ± 16.0 30.2 ± 16.6 45.3 ± 21.1
P-value < 0.001 0.071  0.033
HOMA-B
Baseline, mean ± SD 44.6 ± 48.7 56.3 ± 68.2
Least squares mean change ± SE 11.3 ± 5.3 17.3 ± 5.3 − 5.9 ± 6.9
P-value 0.033 0.001 0.387
P-values are within-group for changes from baseline and between-groups for treatment difference.Original article 761
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deviations were large in each case. A statistically significant
increase was observed in both treatment groups after 24 weeks,
but the difference between treatments was not significant.
Safety and hypoglycaemia incidence
There were no deaths during the study. The incidence of seri-
ous adverse events, as well as of adverse events (AEs) causing
dose interruption or dose change, was low and comparable
between groups. Discontinuations as a result of AEs appeared
to be more frequent in the gliclazide group [eight patients
(6.3%)] compared with the nateglinide group [two patients
(1.5%)]; for nateglinide + metformin, none of the AEs leading
to discontinuation were considered related, but for gliclazide
+ metformin a relationship was suspected in five cases (three
abdominal pain, one nausea, one dizziness/malaise). Infections
and gastrointestinal disorders were the most frequently reported
types of adverse events. No clinically relevant difference for
any AE was noted between treatment groups. The incidence of
all suspected drug-related AEs was low (6.9 and 7.1% in the
nateglinide and gliclazide group, respectively).
The number of patients with at least one event suggestive of
hypoglycaemia was similar between treatment groups, and the
number of patients with more than one confirmed hypoglycaemic
event was similar in the nateglinide group and in the gliclazide
group, as shown in Table 4. The number of clinical symptoms
of hypoglycaemia was nearly twice as high in the gliclazide
group compared with the nateglinide group (15.5 and 28.2
symptoms per 100 patients per month in the nateglinide and
gliclazide groups, respectively). In particular, fewer episodes of
tremor, sweating and asthenia was reported in the nateglinide
group: episodes of sweating (2.2 and 7.7 per 100 patients per
month in the nateglinide and gliclazide groups, respectively),
tremor (3.3 and 8.6 per 100 patients per month) and asthenia
(1.2 and 5.6 per 100 patients and month).
Discussion
The reduction in HbA1c was similar when either nateglinide or
gliclazide were added to metformin in patients who were not
adequately controlled with metformin monotherapy. The degree
to which the HbA1c levels were lowered is in agreement with
previous studies investigating the addition of nateglinide to
metformin [11], or the combination of another insulin secret-
agogue with metformin [5,12]. It is of interest to note that,
when combined with metformin, essentially equivalent efficacy
was achieved with an agent targeting primarily postprandial
glucose (nateglinide/metformin reduced postprandial glucose
excursion to a greater extent than gliclazide/metformin) and
an agent that targets primarily fasting glucose level (gliclazide/
metformin reduced FPG to a greater extent than nateglinide/
metformin), highlighting the importance of the postprandial
period in overall glycaemic exposure [13,14].
The number of patients showing an improvement in HbA1c
was similar for both treatments. However, fewer patients in
the nateglinide combination group achieved the target HbA1c of
less than 7.0% at end point than in the gliclazide group. A
small difference in baseline HbA1c, slightly higher in nateglinide
plus metformin (7.66%) compared with gliclazide plus metformin
(7.57%), may account for this result. Supporting this, the
composite efficacy criteria, i.e. merging an improvement of at
least 0.5% or achieving an HbA1c less than 7.0%, showed the
treatments were comparable.
The changes in FPG concentrations mirrored those observed
for HbA1c. Measures of post-meal glucose control and prandial
insulin secretion were either significantly better in the group of
patients treated with nateglinide plus metformin or showed a
corresponding trend. Control of postprandial hyperglycaemia
is believed to have more of an impact on both micro- and
macrovascular risk factors than reduction of elevated fasting
glucose levels [15]. In a meta-analysis of studies of mortality
in relation to glycaemia, the 2-h blood glucose level was more
predictive of all-cause and cardiovascular death than FPG [16].
Nateglinide and gliclazide were both well tolerated and the
incidence of adverse events was similar in either group. The
number of hypoglycaemic events, particularly asymptomatic
events, was higher than seen in previous trials with nateglinide.
However, this was likely to be because of the recommendation
given to patients in the study to measure blood glucose regularly,
independent of whether they were experiencing symptoms of
hypoglycaemia. Also, the threshold value used to define hypogly-
caemia was 4.0 mmol/l, which was relatively high compared
with the level used routinely in many other clinical trials.
This is the first systematic comparison of the addition of a
meglitinide vs. addition of a sulphonylurea to metformin as
combination therapy in patients who were not adequately
controlled on metformin monotherapy. A very recently
published study in drug-naïve patients given either nateglinide/
metformin or glibenclamide/metformin combination treatment
from the start also showed similar control of HbA1c, but better
Table 4 Number of patients reporting hypoglycaemic events during 24 weeks of treatment with nateglinide or gliclazide in combination with 
metformin
 
 
Nateglinide + metformin 
n = 130
Gliclazide + metformin 
n = 126
Patients with at least one event suggestive of hypoglycaemia, n (%) 32 (24.6) 32 (25.4)
Patients with at least one confirmed event of hypoglycaemia, n (%) 28 (21.5) 28 (22.2)
Patients with ≥ 3 events suggestive of hypoglycaemia, n (%) 13 (10.0) 17 (13.5)
Patients with ≥ 3 events confirmed as hypoglycaemia, n (%) 12 (9.2) 16 (12.7)© 2006 The Authors.
Journal compilation © 2006 Diabetes UK. Diabetic Medicine, 23, 757–762
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postprandial control with nateglinide and better FPG control
with glibenclamide [17]. The results of the present study showed
that adding nateglinide provided similar efficacy to adding
gliclazide to metformin for treatment of Type 2 diabetes,
with HbA1c reduced to a similar extent by either treatment over
the 24 weeks. However, the nateglinide combination reduced
glucose excursions and increased insulin concentrations to a
greater extent than the gliclazide combination after a test meal.
Addition of nateglinide to metformin is an effective treatment
for patients inadequately controlled by metformin alone. Further
studies are being carried out to assess long-term postprandial
glucose control and relationship to diabetic complications.
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